Kennedy’s Disease — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Kennedy’s disease, called bulbospinal muscular atrophy (BSMA), is a rare genetic disorder following an X-linked recessive inheritance pattern characterized by the degeneration of motor neurons leading to muscle wasting in the proximal and bulbar regions. BSMA is caused by an unstable expansion of a CAG triplet repeat (40–62 repeats) in exon 1 of the androgen receptor (AR) gene located on chromosome Xq11–12. The onset of symptoms typically occurs between the ages of 30 and 60 years, and initial clinical manifestations may include tremors, muscle cramps, twitching, fatigue, and slurred speech. With disease progression, patients may experience weakness and wasting of the limb and bulbar muscles, resulting in dysarthria, dysphonia, hanging jaw, tongue wasting, chewing difficulty, and impaired mobility. The disease may be misdiagnosed initially as hereditary spastic paraplegia, spinocerebellar ataxia, other motor neuron diseases, myopathies, neuropathies, or cervical spondylosis. The progression of BSMA is slow, with only one-third of patients requiring a wheelchair 20 years after diagnosis. The prognosis for BSMA is generally favorable, with only a slight decrease in life expectancy.
· The estimated incidence of Kennedy’s disease in the USA is approximately 1 case in 40,000 men.
Thelansis’s “Kennedy’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Kennedy’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Kennedy’s Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Kennedy’s Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
